Relapse of unilateral favorable histology Wilms' tumor: significant clinicopathological factors
- PMID: 23217878
- DOI: 10.1016/j.jpedsurg.2012.09.010
Relapse of unilateral favorable histology Wilms' tumor: significant clinicopathological factors
Abstract
Purpose: To evaluate the clinicopathological features that indicate relapse and suggest a new risk based therapeutic strategy for unilateral Favorable Histology Wilms Tumor (FH-WT).
Materials & methods: Thirty-three patients with unilateral WT were treated in two institutions between 1986 and 2010. Twenty-eight patients with FH-WT received primary nephrectomy according to the National Wilms' Tumor Study (NWTS) or the Japanese Wilms' Tumor Study (JWiTS) protocol. Retrospective analyses of the non-relapsed group (n=23) and the relapsed group (n=5) compared age, gender, tumor laterality, tumor weight, initial tumor stage, known histological subtype, chemotherapy (2 or 3 drugs), and any irradiation delivered. Stages and histological subtypes of the tumors were re-evaluated according to the Japanese staging system.
Results: Five of the twenty-eight tumors relapsed, and one patient died. The initial staging (P=0.029) and the histological subtype (P=0.003) were the only factors indicating relapse. Nine of the twenty-three tumors were histologically classified as blastemal predominant subtype (BPT-WT). Five relapsed.
Conclusion: According to the basic Japanese therapeutic strategy, all patients underwent a primary nephrectomy before chemotherapy. This study suggests that the histological subtype pre-treatment "BPT-WT" should be included as a strong indicator of poor prognosis. Such patients should be treated as a high-risk group.
Copyright © 2012 Elsevier Inc. All rights reserved.
Similar articles
-
The prognostic significance of blastemal predominant histology in initially resected Wilms' tumors: a report from the Study Group for Pediatric Solid Tumors in the Kyushu Area, Japan.J Pediatr Surg. 2012 Dec;47(12):2205-9. doi: 10.1016/j.jpedsurg.2012.09.009. J Pediatr Surg. 2012. PMID: 23217877
-
Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.Klin Padiatr. 2004 May-Jun;216(3):132-40. doi: 10.1055/s-2004-822625. Klin Padiatr. 2004. PMID: 15175957 Clinical Trial.
-
Treatment outcomes in adults with favorable histologic type Wilms tumor-an update from the National Wilms Tumor Study Group.Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1379-84. doi: 10.1016/j.ijrobp.2004.05.057. Int J Radiat Oncol Biol Phys. 2004. PMID: 15590168
-
Current therapy for Wilms' tumor.Oncologist. 2005 Nov-Dec;10(10):815-26. doi: 10.1634/theoncologist.10-10-815. Oncologist. 2005. PMID: 16314292 Review.
-
Adult Wilms' tumor: review of literature.J Oncol Pharm Pract. 2012 Mar;18(1):148-51. doi: 10.1177/1078155210396264. Epub 2011 Jan 19. J Oncol Pharm Pract. 2012. PMID: 21248171 Review.
Cited by
-
Modeling high-risk Wilms tumors enables the discovery of therapeutic vulnerability.Cell Rep Med. 2024 Oct 15;5(10):101770. doi: 10.1016/j.xcrm.2024.101770. Epub 2024 Oct 4. Cell Rep Med. 2024. PMID: 39368485 Free PMC article.
-
The roles of microRNAs in Wilms' tumors.Tumour Biol. 2016 Feb;37(2):1445-50. doi: 10.1007/s13277-015-4514-8. Epub 2015 Dec 3. Tumour Biol. 2016. PMID: 26634744 Review.
-
A Nomogram for Predicting Cancer-Specific Survival in Children With Wilms Tumor: A Study Based on SEER Database and External Validation in China.Front Public Health. 2022 Apr 7;10:829840. doi: 10.3389/fpubh.2022.829840. eCollection 2022. Front Public Health. 2022. PMID: 35462822 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous